Hye Ryun Kim

30PUBLICATIONS
185CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Sep 24, 2026
AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.

|Aug 31, 2026
Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

|Jul 03, 2026
EpCAM+ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response.

|Jun 29, 2026
Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.

Pageof 5

Frequent Collaborators

13 joint publications

Min Hee Hong

7 joint publications

Sang-Jun Ha

4 joint publications

Insuk Lee

3 joint publications

Bhumsuk Keam